MIRA Pharmaceuticals reported positive preclinical PK and formulation results for SKNY-1, showing favorable oral bioavailability and robust brain and liver exposure that support once-daily dosing potential.
Key Highlights:
- Optimized oral formulation demonstrated favorable oral bioavailability after oral administration.
- Pharmacokinetic profile showed peak plasma concentrations ~6–12 hours, supporting once-daily dosing potential.
- Robust brain penetration and substantial liver exposure observed, indicating distribution to pharmacologically relevant tissues.
- Reproducible systemic exposure and target tissue distribution across multiple animals in preclinical studies.
- Findings complement prior efficacy and behavioral data showing weight reduction, lean mass preservation, metabolic improvements, and reduced compulsive feeding and nicotine-seeking behaviors.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.